Introduction: Dermatologists are experts in the skin, hair, and nails. However, it is the authors’ perception that many dermatologists lack comfort in performing nail matrix biopsies. Methods: Concerned for inadequate training, we surveyed US dermatology residents to assess their exposure to this procedure. Results: Of the 130 respondents, 43 were PGY4 residents. Of these, 37.21% had never observed and 62.79% had never performed a nail matrix tangential shave biopsy. Similarly, 32.56% had never observed and 58.14% had never performed a nail matrix punch biopsy. Overall, 83.8% of all residents did not feel comfortable with and 71.5% did not anticipate feeling comfortable with performing nail matrix biopsies by residency completion. Interestingly, size of the training program and presence of a nail expert at the institution did not increase comfort levels in performing nail matrix biopsies (p = 0.348 and p = 1.0, respectively). Additionally, the presence of a nail expert did not affect the number of biopsies observed or performed by residents. The only statistically significant associations were between year of training (p < 0.001) and having a formalized curriculum and comfort with nail matrix biopsies (p = 0.002). Conclusions: Our survey highlights a potential lack of instruction in performing nail matrix biopsies in US dermatology residencies and calls for improved resident education.
{"title":"We Need to Nail It: Dermatology Resident Survey Highlighting Lack of Education for Nail Matrix Biopsies","authors":"A. C. Gamret, Ella Glaser, Brian W. Morrison","doi":"10.1159/000540490","DOIUrl":"https://doi.org/10.1159/000540490","url":null,"abstract":"Introduction: Dermatologists are experts in the skin, hair, and nails. However, it is the authors’ perception that many dermatologists lack comfort in performing nail matrix biopsies. Methods: Concerned for inadequate training, we surveyed US dermatology residents to assess their exposure to this procedure. Results: Of the 130 respondents, 43 were PGY4 residents. Of these, 37.21% had never observed and 62.79% had never performed a nail matrix tangential shave biopsy. Similarly, 32.56% had never observed and 58.14% had never performed a nail matrix punch biopsy. Overall, 83.8% of all residents did not feel comfortable with and 71.5% did not anticipate feeling comfortable with performing nail matrix biopsies by residency completion. Interestingly, size of the training program and presence of a nail expert at the institution did not increase comfort levels in performing nail matrix biopsies (p = 0.348 and p = 1.0, respectively). Additionally, the presence of a nail expert did not affect the number of biopsies observed or performed by residents. The only statistically significant associations were between year of training (p < 0.001) and having a formalized curriculum and comfort with nail matrix biopsies (p = 0.002). Conclusions: Our survey highlights a potential lack of instruction in performing nail matrix biopsies in US dermatology residencies and calls for improved resident education.","PeriodicalId":21844,"journal":{"name":"Skin Appendage Disorders","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141929410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-01Epub Date: 2024-04-29DOI: 10.1159/000538621
Michela Valeria Rita Starace, Aditya K Gupta, Mary A Bamimore, Mesbah Talukder, Federico Quadrelli, Bianca Maria Piraccini
Introduction: Oral finasteride and topical minoxidil are long-standing androgenetic alopecia (AGA) treatments; topical finasteride is a more recent medicine. Few studies have compared their therapeutic effects in postmenopausal women. We compared the therapeutic impact of topical finasteride (1-4 sprays of 0.25% topical finasteride solution daily for 12 months), oral finasteride (2.5 mg oral finasteride once daily for 12 months), and topical minoxidil (1 mL of topical minoxidil 5% twice daily for 12 months) in postmenopausal women with AGA.
Methods: We conducted Bayesian network meta-analyses of individual patient-level data insofar as four clinically relevant endpoints, namely, 12-month change in (1) total hair density, (2) hair diameter, (3) clinical photographs, and (4) patients' opinion of efficacy. Data were obtained through medical charts. Regimens' surface under the cumulative ranking distribution (SUCRA) values and relative effects - as per odds ratios - were computed.
Results: As per SUCRA, the most and least effective regimens - across the four outcomes - were oral finasteride, and topical finasteride, respectively; however, no significant statistical differences were found (i.e., p > 0.05).
Conclusion: Oral finasteride is ranked more effective than the topical forms of minoxidil and finasteride; however, more studies are needed to confirm this result.
介绍：口服非那雄胺和外用米诺地尔是治疗雄激素性脱发（AGA）的长期药物，而外用非那雄胺则是较新的药物。很少有研究比较这两种药物对绝经后妇女的治疗效果。我们比较了外用非那雄胺（0.25% 非那雄胺外用溶液，每天 1-4 喷，12 个月）、口服非那雄胺（2.5 毫克非那雄胺口服液，每天一次，12 个月）和外用米诺地尔（5% 米诺地尔外用溶液，1 毫升，每天两次，12 个月）对绝经后 AGA 妇女的治疗效果：我们对患者个人层面的数据进行了贝叶斯网络荟萃分析，这些数据涉及四个临床相关终点，即 12 个月内(1)总毛发密度、(2)毛发直径、(3)临床照片和(4)患者对疗效的看法的变化。数据通过病历获得。结果：根据 SUCRA，在四种结果中，最有效和最无效的治疗方案分别是口服非那雄胺和外用非那雄胺，但没有发现显著的统计学差异（即 p > 0.05）：结论：与米诺地尔和非那雄胺外用药相比，口服非那雄胺的疗效更佳；然而，还需要更多的研究来证实这一结果。
{"title":"The Comparative Effects of Monotherapy with Topical Minoxidil, Oral Finasteride, and Topical Finasteride in Postmenopausal Women with Pattern Hair Loss: A Retrospective Cohort Study.","authors":"Michela Valeria Rita Starace, Aditya K Gupta, Mary A Bamimore, Mesbah Talukder, Federico Quadrelli, Bianca Maria Piraccini","doi":"10.1159/000538621","DOIUrl":"10.1159/000538621","url":null,"abstract":"<p><strong>Introduction: </strong>Oral finasteride and topical minoxidil are long-standing androgenetic alopecia (AGA) treatments; topical finasteride is a more recent medicine. Few studies have compared their therapeutic effects in postmenopausal women. We compared the therapeutic impact of topical finasteride (1-4 sprays of 0.25% topical finasteride solution daily for 12 months), oral finasteride (2.5 mg oral finasteride once daily for 12 months), and topical minoxidil (1 mL of topical minoxidil 5% twice daily for 12 months) in postmenopausal women with AGA.</p><p><strong>Methods: </strong>We conducted Bayesian network meta-analyses of individual patient-level data insofar as four clinically relevant endpoints, namely, 12-month change in (1) total hair density, (2) hair diameter, (3) clinical photographs, and (4) patients' opinion of efficacy. Data were obtained through medical charts. Regimens' surface under the cumulative ranking distribution (SUCRA) values and relative effects - as per odds ratios - were computed.</p><p><strong>Results: </strong>As per SUCRA, the most and least effective regimens - across the four outcomes - were oral finasteride, and topical finasteride, respectively; however, no significant statistical differences were found (i.e., <i>p ></i> 0.05).</p><p><strong>Conclusion: </strong>Oral finasteride is ranked more effective than the topical forms of minoxidil and finasteride; however, more studies are needed to confirm this result.</p>","PeriodicalId":21844,"journal":{"name":"Skin Appendage Disorders","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11299975/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141898261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
J. Piquero-Casals, D. Saceda-Corralo, S. Aladren, Javier Bustos, Alfonso Fernández-Botello, Albert Navasa, Georgina Logusso, Eric Jourdan, J. Mir-Bonafé, Daniel Morgado-Carrasco
Introduction: Chronic telogen effluvium (TE) and androgenetic alopecia represent two prevalent forms of hair loss that can significantly impact individuals’ quality of life. Insufficiency of essential micronutrients has been associated with hair loss. The objective of this study was to evaluate the safety and efficacy of an oral supplement containing l-Cystine, Serenoa repens, Cucurbita pepo, Pygeum africanum, vitamins, and micronutrients in chronic TE (CTE) and androgenetic alopecia (AGA). Methods: Eighty patients of both sexes aged 18–60 years with CTE or AGA were randomized to receive one capsule daily of the oral supplement or placebo for 6 months. Dermatological evaluations, clinical pictures and phototrichograms were done at baseline, 3 months and 6 months. The overall hair volume and appearance were assessed before and after treatment as well as subject’s self-assessment via standardized questionnaire. Results: Hair density increased by 9.9 hairs/cm2 after 3 months and 12.3 hairs/cm2 after 6 months in the oral supplement group and it is statistically significant when compared to placebo. Overall hair volume after 1, 3, and 6 months is better in the supplement group than in the placebo group. The oral supplement was well tolerated. No moderate or severe adverse events were reported. Conclusion: Oral supplementation can increase hair density, anagen hairs, and overall hair appearance in patients with AGA or CTE.
{"title":"Oral Supplementation with l-Cystine, Serenoa repens, Cucurbita pepo, and Pygeum africanum in Chronic Telogen Effluvium and Androgenetic Alopecia: A Double-Blind, Placebo-Controlled, Randomized Clinical Study","authors":"J. Piquero-Casals, D. Saceda-Corralo, S. Aladren, Javier Bustos, Alfonso Fernández-Botello, Albert Navasa, Georgina Logusso, Eric Jourdan, J. Mir-Bonafé, Daniel Morgado-Carrasco","doi":"10.1159/000540081","DOIUrl":"https://doi.org/10.1159/000540081","url":null,"abstract":"Introduction: Chronic telogen effluvium (TE) and androgenetic alopecia represent two prevalent forms of hair loss that can significantly impact individuals’ quality of life. Insufficiency of essential micronutrients has been associated with hair loss. The objective of this study was to evaluate the safety and efficacy of an oral supplement containing l-Cystine, Serenoa repens, Cucurbita pepo, Pygeum africanum, vitamins, and micronutrients in chronic TE (CTE) and androgenetic alopecia (AGA). Methods: Eighty patients of both sexes aged 18–60 years with CTE or AGA were randomized to receive one capsule daily of the oral supplement or placebo for 6 months. Dermatological evaluations, clinical pictures and phototrichograms were done at baseline, 3 months and 6 months. The overall hair volume and appearance were assessed before and after treatment as well as subject’s self-assessment via standardized questionnaire. Results: Hair density increased by 9.9 hairs/cm2 after 3 months and 12.3 hairs/cm2 after 6 months in the oral supplement group and it is statistically significant when compared to placebo. Overall hair volume after 1, 3, and 6 months is better in the supplement group than in the placebo group. The oral supplement was well tolerated. No moderate or severe adverse events were reported. Conclusion: Oral supplementation can increase hair density, anagen hairs, and overall hair appearance in patients with AGA or CTE.","PeriodicalId":21844,"journal":{"name":"Skin Appendage Disorders","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141801391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: Hair loss is a very common complaint in dermatologists’ offices, requiring the use of proven safe and effective therapies to improve the condition without jeopardizing patients’ health and well-being. Methods: We selected 100 male patients with androgenetic alopecia beginning treatment with low dose oral minoxidil to observe incidence and frequency of side effects. Results: The side-effects/symptoms observed in the assessed patients included body and facial hypertrichosis (most incidents), lower legs edema, periorbital edema, fatigue, tachycardia, and insomnia. Dizziness, hypotension, respiratory changes, and diarrhea were expected although not found in the assessed participants. No life-threatening adverse effects were observed. Conclusion: The doses administered in current research of oral minoxidil presented good safety profile as hair loss treatment, with the most incident side-effect being related to hypertrichosis. Systemic side-effects were infrequent.
{"title":"Side Effects’ Frequency Assessment of Low Dose Oral Minoxidil in Male Androgenetic Alopecia Patients","authors":"Leila David Bloch, Rafaelly Mayara Dantas Carlos","doi":"10.1159/000539969","DOIUrl":"https://doi.org/10.1159/000539969","url":null,"abstract":"Introduction: Hair loss is a very common complaint in dermatologists’ offices, requiring the use of proven safe and effective therapies to improve the condition without jeopardizing patients’ health and well-being. Methods: We selected 100 male patients with androgenetic alopecia beginning treatment with low dose oral minoxidil to observe incidence and frequency of side effects. Results: The side-effects/symptoms observed in the assessed patients included body and facial hypertrichosis (most incidents), lower legs edema, periorbital edema, fatigue, tachycardia, and insomnia. Dizziness, hypotension, respiratory changes, and diarrhea were expected although not found in the assessed participants. No life-threatening adverse effects were observed. Conclusion: The doses administered in current research of oral minoxidil presented good safety profile as hair loss treatment, with the most incident side-effect being related to hypertrichosis. Systemic side-effects were infrequent.","PeriodicalId":21844,"journal":{"name":"Skin Appendage Disorders","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141811101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dimitris Rigopoulos, A. Tsiogka, Dimitrios Malanos, S. Gregoriou
Background: Nail involvement is very frequent in psoriasis and may significantly affect patients’ quality of life due to clinical and functional impairment. In addition, nail psoriasis constitutes a negative prognostic factor for the development of psoriatic arthritis (PsA), even in the absence of cutaneous disease. Summary: Herein we provide an updated review on the diagnostic evaluation of nail psoriasis using clinical assessment and implementation of imaging techniques including dermoscopy, capillaroscopy, ultrasonography, and optical coherence tomography. In addition, we summarize consensus guidelines for the management of nail psoriasis and provide efficacy data on the use of intralesional, topical, and the most recently approved targeted systemic therapies. Key Messages: Physicians should be aware of the importance of prompt diagnosis and management of nail psoriasis, to improve patient outcomes and decrease the risk of PsA development.
{"title":"What Is New in Nail Psoriasis?","authors":"Dimitris Rigopoulos, A. Tsiogka, Dimitrios Malanos, S. Gregoriou","doi":"10.1159/000539727","DOIUrl":"https://doi.org/10.1159/000539727","url":null,"abstract":"Background: Nail involvement is very frequent in psoriasis and may significantly affect patients’ quality of life due to clinical and functional impairment. In addition, nail psoriasis constitutes a negative prognostic factor for the development of psoriatic arthritis (PsA), even in the absence of cutaneous disease. Summary: Herein we provide an updated review on the diagnostic evaluation of nail psoriasis using clinical assessment and implementation of imaging techniques including dermoscopy, capillaroscopy, ultrasonography, and optical coherence tomography. In addition, we summarize consensus guidelines for the management of nail psoriasis and provide efficacy data on the use of intralesional, topical, and the most recently approved targeted systemic therapies. Key Messages: Physicians should be aware of the importance of prompt diagnosis and management of nail psoriasis, to improve patient outcomes and decrease the risk of PsA development.","PeriodicalId":21844,"journal":{"name":"Skin Appendage Disorders","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141815521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aditya K. Gupta, Daniel Taylor, Shruthi Polla Ravi, Tong Wang, M. Talukder
Introduction: Oral antifungals were the earliest treatments to receive approval for the management of onychomycosis and have a long-standing record to support their efficacy. Topical antifungals and device-based treatments have been explored and some implemented in more recent years as alternatives to traditional oral antifungals. The present bibliometric analysis summarizes trends in publication frequency for onychomycosis treatment modalities over time and characterizes their body of literature in terms of types of studies available and relative level of evidence. Methods: A comprehensive literature search was performed using Web of Science and SCOPUS databases. Results: Covering all publications from 1970 to present day, our search identified oral therapeutics n = 295 articles (n = 63 randomized control trials [RCTs]), topical therapeutics n = 358 articles (n = 72 RCTs), and device-based treatments n = 158 articles (n = 37 RCTs). Spikes in research activity surround FDA approval of therapeutics for each treatment modality. Research activity within the last decade has focused on topical and device-based treatments. Evidence for efficacy of device-based treatments is lacking from relatively few high-quality RCTs. Conclusion: With growing concern for non-dermatophyte mold onychomycosis and terbinafine resistance, researchers should validate the efficacy and safety of device-based treatments with high-quality studies.
简介：口服抗真菌药物是最早获准用于治疗甲癣的药物，其疗效长期有效。近年来，人们开始探索外用抗真菌药物和基于设备的治疗方法，其中一些已成为传统口服抗真菌药物的替代品。本文献计量分析总结了随着时间的推移，股癣治疗方法的发表频率趋势，并从现有研究类型和相对证据水平的角度描述了这些方法的文献特征。方法：使用 Web of Science 和 SCOPUS 数据库进行了全面的文献检索。结果：我们的检索涵盖了从 1970 年至今的所有出版物，发现了口服药物疗法 n = 295 篇文章（n = 63 项随机对照试验 [RCT]）、局部疗法 n = 358 篇文章（n = 72 项随机对照试验）和基于设备的疗法 n = 158 篇文章（n = 37 项随机对照试验）。每种治疗方式的研究活动都是在美国食品及药物管理局批准治疗方法的前后激增的。过去十年的研究活动主要集中在局部治疗和器械治疗方面。基于设备的治疗方法的疗效证据相对较少，高质量的 RCT 研究也相对较少。结论：随着人们对非皮癣霉菌性甲癣和特比萘芬耐药性的关注与日俱增，研究人员应通过高质量的研究来验证基于设备的治疗方法的有效性和安全性。
{"title":"Treatments for Onychomycosis: A Bibliometric Analysis","authors":"Aditya K. Gupta, Daniel Taylor, Shruthi Polla Ravi, Tong Wang, M. Talukder","doi":"10.1159/000539822","DOIUrl":"https://doi.org/10.1159/000539822","url":null,"abstract":"Introduction: Oral antifungals were the earliest treatments to receive approval for the management of onychomycosis and have a long-standing record to support their efficacy. Topical antifungals and device-based treatments have been explored and some implemented in more recent years as alternatives to traditional oral antifungals. The present bibliometric analysis summarizes trends in publication frequency for onychomycosis treatment modalities over time and characterizes their body of literature in terms of types of studies available and relative level of evidence. Methods: A comprehensive literature search was performed using Web of Science and SCOPUS databases. Results: Covering all publications from 1970 to present day, our search identified oral therapeutics n = 295 articles (n = 63 randomized control trials [RCTs]), topical therapeutics n = 358 articles (n = 72 RCTs), and device-based treatments n = 158 articles (n = 37 RCTs). Spikes in research activity surround FDA approval of therapeutics for each treatment modality. Research activity within the last decade has focused on topical and device-based treatments. Evidence for efficacy of device-based treatments is lacking from relatively few high-quality RCTs. Conclusion: With growing concern for non-dermatophyte mold onychomycosis and terbinafine resistance, researchers should validate the efficacy and safety of device-based treatments with high-quality studies.","PeriodicalId":21844,"journal":{"name":"Skin Appendage Disorders","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2024-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141819503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hunter J. Pyle, Taylor Dyson, Aditi Gadre, T. Harris-Tryon, Crystal Aguh
Introduction: Aberrant fibrosis in central centrifugal cicatricial alopecia (CCCA) is thought to be driven by persistent low-grade inflammation, but the source of inflammation is unclear. Alterations in the scalp microbiota may contribute to inflammation and thus provide a target for therapeutic intervention. We sought to compare the bacterial and fungal cutaneous scalp microbiota in patients with CCCA versus controls. Methods: Six patients with CCCA and seven controls were sampled at the vertex scalp. 16S rRNA sequencing of V3-V4 region and internal transcribed spacer amplicon sequencing was used to compare bacterial and fungal microbiomes. Results: A significantly higher relative abundance of Corynebacterium was noted in patients with CCCA versus controls. No significant difference in scalp fungal or bacterial microbiota composition was observed. Limitations: V3-V4 sequencing can be limited in detection of major skin bacterial species. Conclusion: CCCA is characterized by a distinct bacterial microbiome community and high relative abundances of Corynebacterium. Future studies should characterize the relationship between Corynebacterium and scalp inflammation and the role it may play in the progression of CCCA.
{"title":"A Pilot Study Characterization of the Scalp Microbiome in Central Centrifugal Cicatricial Alopecia Shows Shift in Corynebacterium","authors":"Hunter J. Pyle, Taylor Dyson, Aditi Gadre, T. Harris-Tryon, Crystal Aguh","doi":"10.1159/000539763","DOIUrl":"https://doi.org/10.1159/000539763","url":null,"abstract":"Introduction: Aberrant fibrosis in central centrifugal cicatricial alopecia (CCCA) is thought to be driven by persistent low-grade inflammation, but the source of inflammation is unclear. Alterations in the scalp microbiota may contribute to inflammation and thus provide a target for therapeutic intervention. We sought to compare the bacterial and fungal cutaneous scalp microbiota in patients with CCCA versus controls. Methods: Six patients with CCCA and seven controls were sampled at the vertex scalp. 16S rRNA sequencing of V3-V4 region and internal transcribed spacer amplicon sequencing was used to compare bacterial and fungal microbiomes. Results: A significantly higher relative abundance of Corynebacterium was noted in patients with CCCA versus controls. No significant difference in scalp fungal or bacterial microbiota composition was observed. Limitations: V3-V4 sequencing can be limited in detection of major skin bacterial species. Conclusion: CCCA is characterized by a distinct bacterial microbiome community and high relative abundances of Corynebacterium. Future studies should characterize the relationship between Corynebacterium and scalp inflammation and the role it may play in the progression of CCCA.","PeriodicalId":21844,"journal":{"name":"Skin Appendage Disorders","volume":null,"pages":null},"PeriodicalIF":1.4,"publicationDate":"2024-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141820404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：